Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data

Abstract

BackgroundLimited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients.MethodsA biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treatment between 2010 and 2015. To account for different cancer stages, two patient populations were analyzed. The first group consisted of patients on medication for hormone-sensitive prostate cancer (HSPC). The second group is comprised of patients who ended up receiving specific therapy for castration-resistant prostate cancer (CRPC). For each treatment, the average of treatment duration and the portion of patients transitioning to a consecutive treatment was calculated.ResultsWe identified 59,626 patients from the Japanese administrative database with a PCA diagnosis and specific treatment. In the first year of our observational study 786 patients commenced a HSPC treatment and 695 received a CRPC specific therapy Among the HSPC group, we found that combination hormonal therapy, comprised of a gonadotrophin releasing hormone agonist or antagonist with an antiandrogen was more common than monotherapy. The results of the CRPC group indicated that chemotherapy administration was for a shorter time period in a real-world setting as compared to published clinical studies.ConclusionUtilizing a novel method to visualize real-world treatment pathways for PCA patients we found that real treatment pathways are in line with international guidelines.

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus

“…[ 20 ] Previously, the MDV database has been used to examine a wide range of medical conditions in Japan such as rheumatoid arthritis, [ 21 – 23 ] schizophrenia, [ 24 ] infectious diseases, [ 25 ] multiple sclerosis, [ 26 ] hypertension, [ 27 ] or prostate cancer. [ 28 , 29 ] We considered the inpatient claims from patients with hospital admission between April 1, 2014 and March 31, 2015 and at least 1 confirmed RSV-related diagnosis (International Classification of Diseases 10th Revision codes: J12.1, J20.5, J21.0, and B34.8) as well as a minimum hospital stay of 2 days (confirmed by at least 1-night stay in the hospital). We limited our analysis to patients of up to 5 years of age.…”

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

“…Costs that occur outside this hospital network are not captured. The database had been used in health economic or epidemiological analyses of many different indications such as schizophrenia [ 15 ], influenza [ 16 ], infectious diseases [ 17 ], RA [ 18 , 19 ], cardiovascular disease [ 20 ], diabetes [ 21 ], and prostate cancer [ 22 , 23 ]. The time span of our analysis was from March 2009 to September 2015.…”

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

“…Hormonal therapy with bicalutamide is commonly used as firstand second-line therapy in Japan, whereas local radiation or surgery is preferred in Western countries. 22,23 Furthermore, docetaxel, a treatment recommended for mHSPC, is not currently covered by public insurance as initial therapy for mHSPC in Japan. Unlike in the overall population, no differences were observed in ORR between Japanese treatment arms.…”